ReviewACS pharmacology & translational science2026

Chimeric Antigen Receptor T‑Cell Therapy Targeting Tumor Necrosis Factor Receptor Superfamily Member 8 (CD30) for Relapsed or Refractory Anaplastic Large Cell Lymphoma: Rationale, Strategies, and Emerging Clinical Evidence.

Alberto BorettiPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.